Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients

Trial Profile

Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Jan 2018 to 31 Jan 2018.
    • 15 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 17 Jan 2018.
    • 13 Sep 2016 Number of treatment arms changed from 2 to 4.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top